53957-59-8Relevant academic research and scientific papers
Cu(I) Catalyzed 1,3-Dipolar Click Synthesis of S-Heterocyclic 1,2,3-Triazole Derivatives, Their Antibacterial Activity
Hemanth, K.,Kalluraya, B.,Revanasiddappa, B. C.,Turukarabettu, V.
, p. 142 - 147 (2020)
A novel series of 1,2,3-triazoles is synthesized by 1,3-dipolar cycloaddition of aromatic azides and terminal alkynes containing 1,2,4-triazole/1,3,4-oxadiazole in presence of Cu(I) catalyst in aqueous medium. The compounds are characterized by spectral and analytical data. The novel triazoles demonstrate moderate to excellent antibacterial activity and good docking score.
Synthesis of new 1, 3, 4-oxadiazole-incorporated 1, 2, 3-triazole moieties as potential anticancer agents targeting thymidylate synthase and their docking studies
Alam, Mohammad Mahboob,Almalki, Abdulraheem S. A.,Neamatallah, Thikryat,Ali, Nada M.,Malebari, Azizah M.,Nazreen, Syed
, p. 1 - 15 (2020/11/19)
Thymidylate synthase (TS) has emerged as a hot spot in cancer treatment, as it is directly involved in DNA synthesis. In the present article, nine hybrids containing 1,2,3-triazole and 1,3,4-oxadiazole moieties (6–14) were synthesized and evaluated for anticancer and in vitro thymidylate synthase activities. According to in silico pharmacokinetic studies, the synthesized hybrids exhibited good drug likeness properties and bioavailability. The cytotoxicity results indicated that compounds 12 and 13 exhibited remarkable inhibition on the tested Michigan Cancer Foundation (MCF-7) and Human colorectal Carcinoma (HCT-116) cell lines. Compound 12 showed four-fold inhibition to a standard drug, 5-fluoruracil, and comparable inhibition to tamoxifen, whereas compound 13 exerted five-fold activity of tamoxifen and 24-fold activity of 5-fluorouracil for MCF-7 cells. Compounds 12 and 13 inhibited thymidylate synthase enzyme, with an half maximal inhibitory concentration, IC50 of 2.52 μM and 4.38 μM, while a standard drug, pemetrexed, showed IC50 = 6.75 μM. The molecular docking data of compounds 12 and 13 were found to be in support of biological activities data. In conclusion, hybrids (12 and 13) may inhibit thymidylate synthase enzyme, which could play a significant role as a chemotherapeutic agent.
Rational design, synthesis and biological evaluation of 1,3,4-oxadiazole pyrimidine derivatives as novel pyruvate dehydrogenase complex E1 inhibitors
He, Haifeng,Wang, Wei,Zhou, Yuan,Xia, Qin,Ren, Yanliang,Feng, Jiangtao,Peng, Hao,He, Hongwu,Feng, Lingling
, p. 1879 - 1888 (2016/04/05)
On the basis of previous study on 2-methylpyrimidine-4-ylamine derivatives I, further synthetic optimization was done to find potent PDHc-E1 inhibitors with antibacterial activity. Three series of novel pyrimidine derivatives 6, 11 and 14 were designed and synthesized as potential Escherichia coli PDHc-E1 inhibitors by introducing 1,3,4-oxadiazole-thioether, 2,4-disubstituted-1,3-thiazole or 1,2,4-triazol-4-amine-thioether moiety into lead structure I, respectively. Most of 6, 11 and 14 exhibited good inhibitory activity against E. coli PHDc-E1 (IC50 0.97-19.21 μM) and obvious inhibitory activity against cyanobacteria (EC50 0.83-9.86 μM). Their inhibitory activities were much higher than that of lead structure I. 11 showed more potent inhibitory activity against both E. coli PDHc-E1 (IC50 50 50 = 0.97 μM) and cyanobacteria (EC50 = 0.83 μM). The possible interactions of the important residues of PDHc-E1 with title compounds were studied by molecular docking, site-directed mutagenesis, and enzymatic assays. The results indicated that 11d had more potent inhibitory activity than that of 14d or I due to its 1,3,4-oxadiazole moiety with more binding position and stronger interaction with Lsy392 and His106 at active site of E. coli PDHc-E1.
Synthesis and evaluation of some substituted heterocyclic fluconazole analogues as antifungal agents
Wang, Shudong,Zhang, Lei,Jin, Yongsheng,Tang, Jin Hao,Su, Hua,Yu, Shichong,Ren, Haixiang
, p. 2362 - 2364 (2014/06/09)
A new series of fluconazole analogues of 1-(1H-1,2,4-triazol-1-yl)-2-(2,4- difluoro-phenyl)-3-4-(substituted-heterocyclic ring-1H-1,2,3- triazol-1-yl)-2-propanols (1-10) were designed, synthesized and evaluated as antifungal agents. Preliminary antifungal tests showed that most of the title compounds exhibited moderate activity with broad spectrum against eight human pathogenic fungi in vitro, compounds 1 and 6 had the best antifungal activity against Candida albicans with the value of MIC80 = 0.5 μg/mL respectively.
